ReForm Biologics Names Industry Veteran Jeff Hackman as President and Chief Executive Officer | Business Wire

WOBURN, Mass.–( BUSINESS WIRE )– ReForm Biologics , Inc., a company developing a new generation of innovative biologic medicines to improve patient access, safety, and convenience, today announced the appointment of Jeffrey S. Hackman as President and Chief Executive Officer (CEO). ReForm also announced that John Sorvillo, the immediate past CEO, will stay on with the company as Chair of the Advisory Board.

Read the source article at businesswire.com
2021-09-08 01:00:00